Making cervical cancer screening more effective and objective
Today, women have an 80% chance in their lifetimes of contracting high-risk HPV, the causal agent of cervical cancer. However, only 1 in 10 women with high-risk HPV will develop long-lasting infections that put them at risk for development of cervical cancer.2 There is growing need for an accurate molecular test to see beyond HPV and determine whether a patient has a high short-term risk of cervical cancer.
QIAsure delivers objective assurance that women are safe from cervical cancer following a positive high-risk HPV result or an abnormal cytology result.
- Separate out patients with high-risk HPV infections that are transforming into cervical cancer from patients who have low short-term risk of developing cancer
- Guide surveillance and treatment decisions
- Prevent women with non-transforming infections from receiving unnecessary treatments
Key Benefits of QIAsure
QIAsure is a quantitative methylation specific PCR test with high sensitivity and 100% accuracy in detecting biomarkers associated with cervical carcinoma in patients.
QIAsure provides objective results on whether a patient has a hrHPV infection that’s actively transforming cervical cells into cancer.
QIAsure can be performed on the same sample (self-sample or physician/OBGYN collected) as the primary screening HPV test.
QIAsure can help reduce unnecessary colposcopies and cervical treatments.
QIAsure can be performed on self-samples collected by the patient without a speculum exam, making it easy and convenient to be tested early and often.
QIAsure provides test negative patients with peace of mind that they have a low short-term risk of cervical cancer.